Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 14/20 | 0.67 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.67 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PPIA | P62937 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241610 | 0.86 | CYP19A1 (0.55) | PTGDR2CYP19A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL31418722 | 0.85 | MEN1 (0.70) | CYP19A1CYP11B1CYP11B2MEN1MAPT | |
| SCHEMBL371728 | 0.85 | MEN1 (0.70) | CYP19A1CYP11B1CYP11B2MEN1MAPT | |
| SCHEMBL7825518 | 0.82 | MEN1 (0.67) | CYP19A1CYP11B1CYP11B2MEN1MAPT | |
| SCHEMBL6572912 | 0.82 | CYP19A1 (0.62) | PTGDR2CYP19A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL8737543 | 0.82 | MEN1 (0.56) | PTGDR2CYP19A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL8737109 | 0.82 | MEN1 (0.56) | PTGDR2CYP19A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL214776 | 0.82 | MEN1 (0.62) | PTGDR2CYP19A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL1753562 | 0.82 | PTGDR2 (1.00) | PTGDR2CYP19A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL9812697 | 0.82 | PTGDR2 (0.67) | PTGDR2CYP19A1CYP11B1CYP11B2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984331-B1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORP (US) | 2010-10-20 | — | — | EP | disclosed |
| US-7807672-B2 | Compounds that are ERK inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807672-B2 | Compounds that are ERK inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| CN-101415674-A | Pyrrolidine derivatives as ERK inhibitors | SCHERING CORP (US) | 2009-04-22 | — | — | CN | disclosed |
| EP-1984331-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | PTGDR2 1548/4885CYP19A1 1395/4885CYP11B1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.